Abstract
The odd‐skipped related 1 (OSR1) gene encodes a zinc‐finger transcription factor. The expression and significance of OSR1 in human tumors remains unclear. We found that OSR1 was downregulated in lung cancers, and its expression was correlated with poor differentiation. Overexpression of OSR1 by OSR1 gene transfection into H1299 cells (H1299‐OSR1) inhibited the proliferation and invasion of lung cancer cells. Knockdown of OSR1 with small interfering (si)RNA against OSR1 in A549 cells (A549‐siOSR1) enhanced the proliferation and invasion of lung cancer cells. Western blot analysis showed that the expression level of GSK3β increased, while that of p‐GSK3β, nuclear β‐catenin, cyclin D1, c‐Myc and matrix metallopeptidase 7 significantly decreased in the H1299‐OSR1 cells, and this pattern was reversed in the A549‐siOSR1 cells compared to that in the control cells. Furthermore, upregulation of sex‐determining region Y‐box 9 (SOX9) by SOX9 gene transfection increased the expression of β‐catenin, which was inhibited by OSR1. The mRNA and protein expression levels of SOX9 and β‐catenin were reduced in H1299‐OSR1 cells and increased in A549‐siOSR1 cells. In conclusion, the expression of OSR1 was more reduced in lung cancer tissues than in normal lung tissues, and was correlated with poor differentiation. OSR1 downregulated the activity of the Wnt signaling pathway by suppressing the expression of SOX9 and β‐catenin.
Keywords: β‐catenin, lung cancer, OSR1, SOX9, Wnt signaling pathway
1. INTRODUCTION
Lung cancer is the second most common malignant tumor and the leading cause of cancer deaths worldwide.1, 2 Many complex factors play important roles in the growth and invasion of tumor cells.3, 4 The overall 5‐year survival of patients with lung cancer remains very low. Effective biomarkers for the early detection, diagnosis, prognosis and monitoring of lung cancer are urgently needed.4, 5
The odd‐skipped related 1 (OSR1) gene, located on human chromosome 2p24.1, encodes a zinc‐finger transcription factor.6 OSR1 plays important roles in the development of the intermediate mesoderm. During this process, multiple factors interact with OSR1. Bone morphogenetic protein7 and 1,25‐dihydroxyvitamin D3 can activate OSR1,8 whereas runt related transcription factor 2 and IKAROS family zinc finger 1 can repress it.9 OSR1 is also essential for embryonic heart and urogenital formation, and the development of the tongue and kidneys.10, 14 However, the biological relationship between OSR1 and cancer biology has not yet been well‐characterized, except in gastric cancer and renal cell carcinoma.15, 16 Otani et al15 demonstrated that OSR1 mediated tumor suppressive effects through the activation of p53 pathway and the repression of the Wnt/β‐catenin signaling pathway in gastric cancer. The Wnt signaling pathway is essential in both normal embryonic development and a variety of cancers.17, 19 This signaling pathway is exquisitely regulated by a large and complex array of proteins, among which β‐catenin is the key protein (Figure 1).20 When the Wnt signal is weak, β‐catenin is incorporated in a destruction complex that contains glycogen synthase kinase 3 (GSK3), adenomatous polyposis coli (APC), axin 1 and casein kinase 1, which results in the phosphorylation of β‐catenin and its degradation by a ubiquitin‐mediated proteasomal pathway.21 However, in human cancers, the dissociation of β‐catenin from this destruction complex results in the accumulation of β‐catenin in the cytoplasm and nucleus, which activates the target genes of the Wnt pathway, such as cyclin D1, matrix metallopeptidase 7 (MMP7) and c‐Myc.22, 23 The detailed mechanism of OSR1‐mediated regulation of the Wnt signaling pathway is unclear. The expression and function of OSR1 in human lung cancer and its underlying molecular mechanisms also need to be explored.
In this study, we examined the expression of OSR1 in lung cancer tissues and corresponding normal lung tissues, and analyzed its correlations with clinicopathological factors. We also investigated the underlying mechanisms of OSR1‐mediated regulation of the Wnt signaling pathway, and its effects on the proliferative and invasive abilities of lung cancer cells.
2. MATERIALS AND METHODS
2.1. Patient data and tissue samples
Tissue specimens from 250 lung cancer patients who underwent complete surgical resection at the First Affiliated Hospital of China Medical University between 2012 and 2015 were selected from the archival files of the Department of Pathology. Some lung cancer samples (126 cases) were accompanied by corresponding normal lung tissue samples. The ages of patients ranged from 20 to 81 years old, with a mean age of 60 years. There were 172 male and 78 female patients. The histological diagnoses and differentiation grades of the tissue samples were classed according to the World Health Organization classification system as squamous cell carcinoma (n = 119) and adenocarcinoma (n = 131).24 The cancers were classified as well‐differentiated (40 cases), moderately differentiated (143 cases) and poorly differentiated (67 cases). According to the seventh edition of the International Union against Cancer TNM Staging System for Lung Cancer,25 patients were categorized as stage I (n = 41), II (n = 147), III (n = 51) or IV (n = 11). Lymph node metastases were found in 126 cases. We also collected 30 pairs of fresh specimens, including both tumor tissues and corresponding normal tissues, which were stored at −80°C immediately after resection. The study was conducted under the regulations of the Institutional Review Board of China Medical University.
2.2. Immunohistochemistry
All resected specimens were fixed in 10% neutral formalin, embedded in paraffin, and sectioned serially into 4‐μm slices. Immunostaining was performed using a streptavidin‐peroxidase method. All sections were deparaffinized in xylene, rehydrated in a graded alcohol series, and boiled in 0.01 mol/L citrate buffer for 2.5 minutes in an autoclave. Endogenous peroxidase activity was blocked using hydrogen peroxide, followed by incubation with normal goat serum to reduce non‐specific binding. The sections were incubated with anti‐OSR1 rabbit polyclonal antibody (1:100; Abcam, Cambridge, MA, USA) at 4°C overnight. Then, the sections were incubated with biotinylated goat anti‐rabbit serum IgG secondary antibody and HRP‐conjugated streptavidin‐biotin (MaiXin, Fuzhou, China). Visualization was performed using DAB chromogen (MaiXin, Fuzhou, China).
Two investigators blinded to the clinical data scored the slides. Five views were examined per slide, and 100 cells were observed per view at 400× magnification. The positive rate for each case was obtained by calculating the percentage of positively stained cells in each slide. The percentage score for each case was categorized as follows: (i) 1%‐25%, (ii) 26%‐50%, (iii) 51%‐75% and (iv) 76%‐100%. The intensity of immunostaining was scored as 0, 1, 2 or 3, if negative, weak, moderate, or marked, respectively. The scores from each tumor sample were multiplied to give a final score ranging from 0 to 12, and the tumors were categorized based on their scores, with ≤6 and ≥8 indicating low and high expression, respectively.26
2.3. Cell culture and transfection
The normal human bronchial epithelial cell line HBE and the human lung cancer cell lines H292, LK2, H460, H661, A549 and H1299 were purchased from American Type Culture Collection (Manassas, VA, USA). The HBE and LK2 cells were cultured in Minimal Essential Medium (Gibco, Invitrogen, NY, USA), whereas the other cells were cultured in RPMI‐1640 (Gibco, Invitrogen, NY, USA), both supplemented with 10% FBS (Gibco, Invitrogen, NY, USA) at 37°C in 5% CO2. The cells were grown in sterile culture dishes and passaged every 1 or 2 days using 0.25% trypsin (Gibco, Invitrogen, NY, USA).
For transfection, cells were seeded in a 6‐well plate 24 hours before the experiment. The pCMV6‐OSR1 plasmid, pCMV6‐SOX9 plasmid, pCMV6‐CTNNB1 plasmid and the control empty vector pCMV6 were purchased from Origene (Rockville, MD, USA). Small interfering (si)RNA against OSR1 (OSR1‐siRNA), SOX9‐siRNA, CTNNB1‐siRNA and control siRNA were synthesized by RIBOBIO (Guangzhou, China). The plasmids or siRNA were transfected into cells using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer's instructions. Semi‐stably transfected cell lines were screened for 4 weeks with G418.
2.4. Real‐time PCR
Real‐time PCR was performed using the SYBR PrimeScript RT‐PCR Kit II (Takara, Dalian, China) in a total volume of 20 μL on a 7500HT Fast Real‐Time PCR system (Applied Biosystems, Carlsbad, CA, USA) as follows: 95°C for 30 seconds, 40 cycles of 95°C for 5 seconds and 60°C for 34 seconds. The primer sequences are listed in Table 1.
Table 1.
Primer name | Sequence (5′‐3′) |
---|---|
OSR1‐F | CGGTGCCTATCCACCCTTC |
OSR1‐R | GCAACGCGCTGAAACCATA |
SOX9‐F | AGCGAACGCACATCAAGAC |
SOX9‐R | CTGTAGGCGATCTGTTGGGG |
β‐catenin‐F | AAAGCGGCTGTTAGTCACTGG |
β‐catenin‐R | CGAGTCATTGCATACTGTCCAT |
GAPDH‐F | ACAACTTTGGTATCGTGGAAGG |
GAPDH‐R | GCCATCACGCCACAGTTTC |
2.5. Western blot
Total protein was extracted from cells in cell lysis buffer (Pierce, Rockford, IL, USA) and quantified using the Bradford method.27 Nuclear/cytoplasmic proteins were separated using NE‐PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific, USA), according to the manufacturer's protocol. A total of 60 μg of protein was separated using 8% sodium dodecyl sulfate polyacrylamide gel electrophoresis, then transferred to a polyvinylidene fluoride membrane (Millipore, Bedford, MA, USA). The membranes were blocked with 5% non‐fat milk and incubated overnight at 4°C with antibodies against OSR1 (1:150, Santa Cruz Biotechnology), SOX9 (1:150, Santa Cruz Biotechnology), β‐catenin (1:100, Santa Cruz Biotechnology), active β‐catenin (1:500, Cell Signaling Technology), GSK3β (1:500, Cell Signaling Technology), p‐GSK3β (1:500, Cell Signaling Technology), cyclin D1 (1:100, Santa Cruz Biotechnology), c‐Myc (1:200, BD Biosciences), MMP7 (1:100, Santa Cruz Biotechnology), LDL receptor related protein 6 (LRP6; 1:100, Santa Cruz Biotechnology), axin (1:100, Santa Cruz Biotechnology), dishevelled segment polarity protein 1 (DVL1; 1:100, Santa Cruz Biotechnology), lymphoid enhancer binding factor 1 (LEF1; 1:100, Santa Cruz Biotechnology), snail (1:500, Cell Signaling Technology), E‐cadherin (1:500, Cell Signaling Technology), N‐cadherin (1:500, Cell Signaling Technology) and glyceraldeyhde‐3‐phosphate dehydrogenase (GAPDH; 1:2000, Santa Cruz Biotechnology). After washing, the membranes were incubated with peroxidase‐conjugated anti‐mouse/rabbit IgG (1:2000, Proteintech) at 37°C for 2 hours. Protein bands were visualized with ECL (Pierce) and detected using a bioimaging system (DNR Bio‐Imaging System, Jerusalem, Israel). The relative protein levels were calculated using GAPDH protein as a loading control. The bands were quantified with Image J software.
2.6. Cell proliferation assay
Twenty‐four hours after transfection, cells were plated in 96‐well plates (3000 cells/well) in medium containing 10% FBS. Cell proliferation was detected using Cell Counting Kit‐8 (CCK‐8, Dojindo Molecular Technologies, Tokyo, Japan). CCK‐8 reagent was added to each well at 1:10 (v/v) per 100 μL and incubated for 2 hours at 37°C. The results were quantitated spectrophotometrically using a test wavelength of 450 nm.
2.7. Colony formation assay
Cells were plated in 6‐cm cell culture dishes (800 cells/dish) 24 hours after transfection, then incubated for 14 days. We changed the medium every 4‐5 days. Cells were fixed with 4% paraformaldehyde for 20 minutes and stained with hematoxylin for 10 minutes. We counted the colonies with more than 50 cells.
2.8. Matrigel invasion assay
We used Matrigel (BD Biosciences, San Jose, CA, USA) and Transwell chambers with a pore size of 8 μm (Costar, Cambridge, MA, USA), according to the manufacturers’ instructions, to assess the invasive ability of transfected cells. Briefly, 100 μL Matrigel (1:7 dilution) was added to each insert. Then, we placed the chambers in a 37°C incubator for at least 2 hours; after gelation of the Matrigel, we added 8 × 104 cells in 100 μL medium supplemented with 2% FBS to the upper chamber. Medium supplemented with 20% FBS was added to the lower chamber as the chemoattractant. After 20 hours of incubation, the filters were fixed with 4% paraformaldehyde for 20 minutes and stained with hematoxylin for 10 minutes. The non‐invading cells on the upper surface were removed by scrubbing with a cotton swab. The numbers of invasive cells were counted in 10 randomly selected high‐power fields under a microscope. The experiments were performed in triplicate.
2.9. Statistical analysis
All statistical analyses were performed using SPSS 17.0 software (Chicago, IL, USA) and GraphPad Prism 6.0 software (La Jolla, CA, USA). The Chi–square‐test was used to examine possible correlations between OSR1 expression and clinicopathological factors. Other results were analyzed using Student's t‐test or the Pearson correlation coefficient. P < .05 was considered to indicate a statistically significant result.
3. RESULTS
3.1. OSR1 expression is downregulated and negatively correlated with β‐catenin expression in lung cancer tissues
The expression of OSR1 was examined in 250 lung cancer tissues and 126 corresponding normal lung tissue specimens using immunohistochemistry. OSR1 was mainly expressed in the cytoplasm, accompanied by nuclear expression in some cells. In corresponding normal lung tissues, 95 cases (75.4%) showed high expression of OSR1 in normal bronchial epithelial cells or alveolar cells (Figure 2A,B), and 31 cases (24.6%) exhibited low expression. In lung cancer tissues, 111 cases (44.4%) had low expression of OSR1 (Figure 2C,E), whereas 139 cases (55.6%) had high expression (Figure 2D,F). The expression rate of OSR1 was lower in lung cancers than in normal lung tissues (P < .001) (Table 2). As listed in Table 2, the low expression of OSR1 correlated significantly with poor differentiation of lung cancers (P = .037). The expression of OSR1 did not correlate with patient age (P = .437) or gender (P = .919), or the histological type (P = .767), TNM stage (P = .130) or lymphatic metastasis (P = .123) of lung cancers.
Table 2.
n | OSR1 low expression | OSR1 high expression | P‐value | |
---|---|---|---|---|
Tissues | ||||
Normal | 126 | 31 (24.6%) | 95 (75.4%) | <.001 |
Lung cancer | 250 | 111 (44.4%) | 139 (55.6%) | |
Age | ||||
<60 | 124 | 52 (41.9%) | 72 (58.1%) | .437 |
≥60 | 126 | 59 (46.8%) | 67 (53.2%) | |
Gender | ||||
Male | 172 | 76 (44.2%) | 96 (55.8%) | .919 |
Female | 78 | 35 (44.9%) | 43 (55.1%) | |
Histological type | ||||
Squamous cell carcinoma | 119 | 54 (45.4%) | 65 (54.6%) | .767 |
Adenocarcinoma | 131 | 57 (43.5%) | 74 (56.5%) | |
Differentiation | ||||
Well‐moderate | 183 | 74 (40.4%) | 109 (59.6%) | .037 |
Poor | 67 | 37 (55.2%) | 30 (44.8%) | |
TNM stages | ||||
I | 41 | 13 (31.7%) | 28 (68.3%) | .130 |
II | 147 | 72 (49.0%) | 75 (51.0%) | |
III‐IV | 62 | 26 (42.0%) | 36 (58.0%) | |
Lymphatic metastasis | ||||
Yes | 126 | 62 (49.2%) | 64 (50.8%) | .123 |
No | 124 | 49 (39.5%) | 75 (60.5%) |
Western blot analysis confirmed that the expression levels of OSR1 were significantly higher in the normal lung tissues than in lung cancer tissues (1.95 ± 0.24 vs 1.07 ± 0.16; n = 30; P < .01) (Figure 3A,B). We examined the expression of OSR1 in 6 lung cancer cell lines and a normal bronchial epithelial cell line (HBE). We found that the expression of OSR1 was lower in 4 of 6 lung cancer cell lines, especially in LK2, H661 and H1299, than in HBE cells (Figure 3C,D). The expression levels of OSR1 and β‐catenin were also examined in 20 pairs of lung cancer tissues and corresponding normal lung tissues. We found that OSR1 expression was negatively correlated with that of β‐catenin in lung cancer tissues (n = 20; correlation coefficient = −0.675; P < .01) (Figure 3E,F).
3.2. OSR1 inhibited the proliferative and invasive abilities of lung cancer cells
To examine the function of OSR1 in lung cancer cells, we elevated the expression of OSR1 by OSR1 gene transfection in H1299 cells (H1299‐OSR1) or downregulated the expression with OSR1 siRNA in A549 cells (A549‐siOSR1). Compared with H1299 cells transfected with the empty control vector (NC), the H1299‐OSR1 cells had significantly higher mRNA and protein expression levels of OSR1 (Figure 4A,B). Overexpression of OSR1 inhibited the invasive ability (P < .01), colony formation (P < .01) and proliferation rate of the lung cancer cells (day 5, P < .05) (Figure 4E‐G). In contrast, compared with A549 cells transfected with control siRNA (siNC), A549‐siOSR1 cells had significantly lower mRNA and protein levels of OSR1 (Figure 4C,D). The downregulation of OSR1 enhanced the invasive ability (P < .01), colony formation (P < .01) and proliferation rate of cancer cells (day 5, P < .05) (Figure 4E‐G).
3.3. OSR1 restrained the expression of β‐catenin and the activity of the Wnt signaling pathway, and regulated the expression of epithelial–mesenchymal transition‐related proteins
We used western blotting to examine important proteins in the Wnt signaling pathway to explore the underlying mechanisms of the effects of OSR1 on lung cancer cell proliferation and invasion. Compared to the control cells, the expression level of GSK3β increased, while that of p‐GSK3β, active β‐catenin and nuclear β‐catenin significantly decreased in the H1299‐OSR1 cells (P < .05). Concomitantly, the expression levels of target genes of the Wnt signaling pathway, such as cyclin D1, c‐Myc and MMP7, were also significantly reduced in H1299‐OSR1 cells (P < .05) (Figure 5A,B). However, the expression levels of axin, DVL1, LRP6 and LEF1 were not markedly changed (P > .05). The expression level of E‐cadherin increased, while N‐cadherin and Snail significantly decreased in the H1299‐OSR1 cells compared to the control cells (P < .05) (Figure 5E). In contrast, compared to the control cells, the expression level of GSK3β decreased, while that of p‐GSK3β, active β‐catenin and nuclear β‐catenin significantly increased in the A549‐siOSR1 cells (P < .05). The expression levels of target genes of the Wnt signaling pathway, such as cyclin D1, c‐Myc and MMP7, were also significantly increased in A549‐siOSR1 cells (P < .05) (Figure 5C,D). As in the cells that overexpressed OSR1, the expression levels of axin, DVL1, LRP6 and LEF1 were not markedly changed (P > .05). The expression level of E‐cadherin decreased, while N‐cadherin and Snail significantly increased in the A549‐siOSR1 cells compared to the control cells (P < .05) (Figure 5F).
3.4. OSR1 downregulated the expression of β‐catenin by inhibiting the transcription of SOX9
A previous study showed that overexpression of OSR1 suppressed the expression of endogenous SOX9 mRNA.11 The expression of β‐catenin increased in the SOX9‐overexpressing glioma cells, suggesting a regulatory role for SOX9 in β‐catenin signaling.28 Thus, we hypothesized that OSR1 may inhibit the expression of β‐catenin by suppressing SOX9 expression. We altered the expression levels of OSR1 and SOX9 in H1299 or A549 cells, both individually and simultaneously. As shown in Figure 6A,B, the mRNA level of β‐catenin was enhanced in H1299 cells transfected with SOX9 compared to control H1299 cells, and reduced in A549 cells transfected with SOX9 siRNA compared to control A549 cells. In addition, compared to the control H1299 cells, the protein level of GSK3β was lower, while that of β‐catenin was higher in the H1299 cells transfected with SOX9. In contrast, compared to the control A549 cells, the protein level of GSK3β was enhanced, while that of β‐catenin was reduced in the A549 cells transfected with SOX9 siRNA (Figure 6C,D). Thus, SOX9 enhanced the expression of β‐catenin at both mRNA and protein levels in lung cancer cells. However, the mRNA and protein levels of SOX9 were reduced in H1299‐OSR1 cells and enhanced in A549‐siOSR1 cells compared to control cells. Overexpression of OSR1 reversed the SOX9‐induced upregulation of β‐catenin and downregulation of GSK3β. Thus, we found that OSR1 inhibited the transcription and expression of SOX9 in lung cancer cells, thereby indirectly downregulating the expression of β‐catenin. We also found that SOX9 could reverse the effects of OSR1 on invasive ability and colony formation of lung cancer cells (Figure 6E‐H).
3.5. Overexpression of β‐catenin can reverse the inhibitory effects of OSR1 in lung cancer cells
To confirm whether the inhibitory effects of OSR1 on lung tumor cell proliferation and invasion were mediated via the inhibition of β‐catenin activity, we altered the expression level of OSR1, or that of OSR1 and β‐catenin (CTNNB1) simultaneously in the H1299 or A549 cells. As shown in Figure 7, overexpression of OSR1 inhibited the invasive ability (P < .01) (Figure 7A), colony formation (P < .05) (Figure 7C), and proliferation rate of lung cancer cells (day 5, P < .05) (Figure 7E). However, when cotransfected with the OSR1 and β‐catenin (CTNNB1) plasmids simultaneously, the inhibitory effects of OSR1 on invasive ability, colony formation and proliferation rate were reversed (Figure 7A,C,E) (P < .05). In contrast, the downregulation of OSR1 enhanced the invasive ability (P < .01) (Figure 7B), colony formation (P < .01) (Figure 7D) and proliferation rate of cancer cells (day 5, P < .01) (Figure 7F). These effects were reduced when OSR1 and β‐catenin (CTNNB1) were simultaneously knocked down (Figure 7B,D,F) (P < .05).
4. DISCUSSION
Previous studies on OSR1 were mostly in the field of embryonic development. Reports of OSR1 in tumors were rare.15, 16 Therefore, the biological relationship between OSR1 and cancer development has not been well‐documented. In our study, we demonstrated that the expression of OSR1 was significantly reduced in lung cancer tissues compared to normal lung tissues, and it correlated with the poor differentiation of lung cancers. These findings were confirmed by the analysis based on TCGA datasets (Figure S1). To date, this is the first report concerning the expression pattern and clinical significance of OSR1 in human lung cancers.
Further in vitro experiments confirmed that the expression of OSR1 inhibited the proliferative and invasive abilities of lung cancer cells. We showed that the expression of OSR1 enhanced the expression of GSK3β, inhibited the expression and activation of β‐catenin, and the expression of Wnt target genes, such as cyclin D1, c‐Myc and MMP7. OSR1 also regulated the expression of epithelial‐mesenchymal transition (EMT)‐related proteins, such as E‐cadherin, N‐cadherin and Snail. Thus, OSR1 acts as a tumor suppressor in lung cancers by restraining the activation of the Wnt signaling pathway and EMT. Otani et al15 also demonstrated that OSR1 activated the p53 pathway and repressed Wnt/β‐catenin signaling in gastric cancers. However, they did not investigate the detailed mechanism of OSR1‐mediated regulation of the Wnt signaling pathway.
As a transcription factor, OSR1 can bind to the promoter of some important genes and regulate their transcriptions. Liu et al11 found that OSR1 could bind to the promoter of the SOX9 gene, and that the overexpression of OSR1 suppressed the expression of endogenous SOX9 mRNA. SOX9 is a high mobility group box transcription factor, which plays critical roles in embryogenesis and human cancers.29, 30, 31, 32 In chondrocyte fate determination and maintenance, SOX9 inhibits Wnt signaling by promoting β‐catenin phosphorylation and subsequent degradation.33 However, Liu et al28 found that the expression of β‐catenin was increased in SOX9‐overexpressing glioma cells, suggesting a regulatory role for SOX9 in β‐catenin signaling. We found, using the Jaspar database (http://jaspar.genereg.net/), that the promoter region of β‐catenin (CTNNB1) contained several SOX9 binding sites. Based on previous reports and our findings, we hypothesized that OSR1 may inhibit the expression of β‐catenin by suppressing SOX9. Our studies confirmed our hypothesis. SOX9 can regulate β‐catenin at the transcriptional level, as well as the stability of proteins GSK3β and β‐catenin. OSR1 inhibited the expression of SOX9 mRNA and protein, and reversed the activating effect of SOX9 on β‐catenin. Thus, OSR1 inhibits the activity of the Wnt signaling pathway by inhibiting the expression of β‐catenin, which is achieved indirectly through the suppression of the transcription of SOX9 (Figure 1).
In conclusion, OSR1 is a novel tumor suppressor gene, which is commonly downregulated in lung cancers, making it a potential tumor malignancy marker and therapeutic target. OSR1 downregulates the expression of β‐catenin and the activity of the Wnt signaling pathway by increasing the expression of GSK3β and suppressing the expression of SOX9.
CONFLICT OF INTEREST
The authors have no conflict of interest to declare.
Supporting information
Wang Y, Lei L, Zheng Y‐W, et al. Odd‐skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and β‐catenin. Cancer Sci. 2018;109:1799–1810. https://doi.org/10.1111/cas.13614
Funding information
National Natural Science Foundation of China (Grant No. 81372497 to H‐T. Xu); Program for Liaoning Excellent Talents in University (Grant No. LR2015067 to H‐T. Xu).
REFERENCES
- 1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer Cell. 2002;1:49‐52. [DOI] [PubMed] [Google Scholar]
- 2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7‐30. [DOI] [PubMed] [Google Scholar]
- 3. Fidler IJ, Kripke ML. Genomic analysis of primary tumors does not address the prevalence of metastatic cells in the population. Nat Genet. 2003;34:23; author reply 5. [DOI] [PubMed] [Google Scholar]
- 4. Lu Y, Li S, Zhu S, Gong Y, Shi J, Xu L. Methylated DNA/RNA in body fluids as biomarkers for lung cancer. Biol Proced Online. 2017;19:2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5. Han Y, Dong Q, Hao J, et al. RASSF4 is downregulated in nonsmall cell lung cancer and inhibits cancer cell proliferation and invasion. Tumour Biol. 2016;37:4865‐4871. [DOI] [PubMed] [Google Scholar]
- 6. Katoh M. Molecular cloning and characterization of OSR1 on human chromosome 2p24. Int J Mol Med. 2002;10:221‐225. [PubMed] [Google Scholar]
- 7. James RG, Schultheiss TM. Bmp signaling promotes intermediate mesoderm gene expression in a dose‐dependent, cell‐autonomous and translation‐dependent manner. Dev Biol. 2005;288:113‐125. [DOI] [PubMed] [Google Scholar]
- 8. Verlinden L, Kriebitzsch C, Eelen G, et al. The odd‐skipped related genes Osr1 and Osr2 are induced by 1,25‐dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2013;136:94‐97. [DOI] [PubMed] [Google Scholar]
- 9. Yamauchi M, Kawai S, Kato T, Ooshima T, Amano A. Odd‐skipped related 1 gene expression is regulated by Runx2 and Ikzf1 transcription factors. Gene. 2008;426:81‐90. [DOI] [PubMed] [Google Scholar]
- 10. Wang Q, Lan Y, Cho ES, Maltby KM, Jiang R. Odd‐skipped related 1 (Odd 1) is an essential regulator of heart and urogenital development. Dev Biol. 2005;288:582‐594. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Liu H, Lan Y, Xu J, Chang CF, Brugmann SA, Jiang R. Odd‐skipped related‐1 controls neural crest chondrogenesis during tongue development. Proc Natl Acad Sci USA. 2013;110:18555‐18560. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12. Tena JJ, Neto A, de la Calle‐Mustienes E, Bras‐Pereira C, Casares F, Gómez‐Skarmeta JL. Odd‐skipped genes encode repressors that control kidney development. Dev Biol. 2007;301:518‐531. [DOI] [PubMed] [Google Scholar]
- 13. Stricker S, Mathia S, Haupt J, Seemann P, Meier J, Mundlos S. Odd‐skipped related genes regulate differentiation of embryonic limb mesenchyme and bone marrow mesenchymal stromal cells. Stem Cells Dev. 2012;21:623‐633. [DOI] [PubMed] [Google Scholar]
- 14. James RG, Kamei CN, Wang Q, Jiang R, Schultheiss TM. Odd‐skipped related 1 is required for development of the metanephric kidney and regulates formation and differentiation of kidney precursor cells. Development. 2006;133:2995‐3004. [DOI] [PubMed] [Google Scholar]
- 15. Otani K, Dong Y, Li X, et al. Odd‐skipped related 1 is a novel tumour suppressor gene and a potential prognostic biomarker in gastric cancer. J Pathol. 2014;234:302‐315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16. Zhang Y, Yuan Y, Liang P, et al. OSR1 is a novel epigenetic silenced tumor suppressor regulating invasion and proliferation in renal cell carcinoma. Oncotarget. 2017;8:30008‐30018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Hubaux R, Thu KL, Lam WL. Re: the Wnt signaling pathway in non‐small cell lung cancer. J Natl Cancer Inst. 2014;106:dju188. [DOI] [PubMed] [Google Scholar]
- 18. Jamieson C, Sharma M, Henderson BR. Targeting the β‐catenin nuclear transport pathway in cancer. Semin Cancer Biol. 2014;27:20‐29. [DOI] [PubMed] [Google Scholar]
- 19. Stewart DJ. Wnt signaling pathway in non‐small cell lung cancer. J Natl Cancer Inst 2014;106:djt356. [DOI] [PubMed] [Google Scholar]
- 20. Yang CM, Ji S, Li Y, Fu LY, Jiang T, Meng FD. β‐Catenin promotes cell proliferation, migration, and invasion but induces apoptosis in renal cell carcinoma. Onco Targets Ther. 2017;10:711‐724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Kimelman D, Xu W. β‐catenin destruction complex: insights and questions from a structural perspective. Oncogene. 2006;25:7482‐7491. [DOI] [PubMed] [Google Scholar]
- 22. Xie XM, Zhang ZY, Yang LH, et al. Aberrant hypermethylation and reduced expression of disabled‐2 promote the development of lung cancers. Int J Oncol. 2013;43:1636‐1642. [DOI] [PubMed] [Google Scholar]
- 23. Xu HT, Yang LH, Li QC, et al. Disabled‐2 and Axin are concurrently colocalized and underexpressed in lung cancers. Hum Pathol. 2011;42:1491‐1498. [DOI] [PubMed] [Google Scholar]
- 24. Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of Tumours of the Lung, Pleura, Thymus, and Heart, 4th edn Lyon, France: IARC; 2015. [DOI] [PubMed] [Google Scholar]
- 25. Goldstraw P. Updated staging system for lung cancer. Surg Oncol Clin N Am. 2011;20:655‐666. [DOI] [PubMed] [Google Scholar]
- 26. Zheng YW, Zhang L, Wang Y, et al. Thyroid cancer 1 (C8orf4) shows high expression, no mutation and reduced methylation level in lung cancers, and its expression correlates with β‐catenin and DNMT1 expression and poor prognosis. Oncotarget. 2017;8:62880‐62890. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein‐dye binding. Anal Biochem. 1976;72:248‐254. [DOI] [PubMed] [Google Scholar]
- 28. Liu H, Liu Z, Jiang B, Peng R, Ma Z, Lu J. SOX9 overexpression promotes glioma metastasis via Wnt/β‐catenin signaling. Cell Biochem Biophys. 2015;73:205‐212. [DOI] [PubMed] [Google Scholar]
- 29. Jiang SS, Fang WT, Hou YH, et al. Upregulation of SOX9 in lung adenocarcinoma and its involvement in the regulation of cell growth and tumorigenicity. Clin Cancer Res. 2010;16:4363‐4373. [DOI] [PubMed] [Google Scholar]
- 30. Huang Z, Hurley PJ, Simons BW, et al. Sox9 is required for prostate development and prostate cancer initiation. Oncotarget. 2012;3:651‐663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31. Leung CO, Mak WN, Kai AK, et al. Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled‐7 mediated Wnt/β‐catenin signaling. Oncotarget. 2016;7:29371‐29386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Matheu A, Collado M, Wise C, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012;72:1301‐1315. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Topol L, Chen W, Song H, Day TF, Yang Y. Sox9 inhibits Wnt signaling by promoting beta‐catenin phosphorylation in the nucleus. J Biol Chem. 2009;284:3323‐3333. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.